Abstract:Abstract Background Lumipulse G automated immunoassays represent the most widely used method for the quantification of Alzheimer’s disease (AD) biomarkers in cerebrospinal fluid (CSF) 1 . Less invasive blood‐based markers confer a promising tool for AD diagnosis at prodromal stages (Mild Cognitive Impairment‐MCI) 2 . Highly sensitive assays for the quantification of amyloid‐beta (Aβ) and phosphorylated Tau‐181 (p‐Tau181) in blood are showing promising results 3 . In this study we evaluated the clinical performance of the available Lumipulse plasma markers for progression to AD. Method A group of 138 patients (22 neurological controls‐NC, 72 MCI and 44 AD) recruited at the Dementia Clinic of Centro Hospitalar Universitário de Coimbra (CHUC) was included. Data regarding baseline CSF levels of Ab42, Ab40, t‐Tau and p‐Tau181 was available, allowing for characterization into ATN categories 4 . Baseline Ab42, Ab40 and p‐Tau181 levels were determined in stored plasma samples using high‐throughput fully automated Lumipulse assays. Progression from MCI to AD dementia was assessed at follow‐up (mean 5.9±3.0 years; 36 converted ‐MCI‐AD/36 stable ‐MCI‐St). Result In the total cohort, correlations between CSF and plasma were moderate for p‐Tau 181 (r = 0.61, p<0.001), weak for Aβ42 (r = 0.28, p = 0.001) and non‐significant for Aβ40 (r = ‐0.05, p = 0.54). Plasma p‐Tau181 levels were significantly increased while Aβ42, Aβ42/Aβ40 and Aβ42/p‐Tau181 were significantly decreased (p<0.001) in patients classified as MCI‐AD and AD in relation both to NC and MCI‐St. Plasma p‐Tau181 showed a robust performance in differentiating NC+MCI‐St vs. MCI‐AD+AD (AUC = 0.89, 95%CI:0.83‐0.94), MCI‐St vs. MCI‐AD (AUC = 0.89, 95%CI:0.81‐0.96) and CSF A+ vs. A‐ (AUC = 0.84, 95%CI:0.77‐0.91). Plasma Aβ42/p‐Tau181 gave similar AUC results (AUCs = 0.88, 0.84 and 0.83) and showed no significant differences compared to p‐Tau181 alone (p = 0.34, 0.33 and 0.92). For MCI‐St vs. MCI‐AD, when maximizing for sensitivity (0.92, specificity 0.67), baseline plasma p‐Tau181 levels higher than 1.69 pg/mL predicted future AD dementia (HR = 11.5; 95%CI = 10.9‐12.1). Conclusion Our results show that the measurement of p‐Tau181 in peripheral blood has great potential as a non‐invasive prognostic screening tool for AD dementia in MCI patients. 1. Delaby C, et al. Alzheimer’s Dement . 2021; 2.Teunissen CE, et al. Lancet Neurol . 2022; 3.Palmqvist S, et al. Nat Med . 2021; 4.Jack CR, et al. Alzheimer’s Dement . 2018

Relationship Between Cerebrospinal Fluid Alzheimer's Disease Biomarker Values Measured via Lumipulse Assays and Conventional ELISA: Single-Center Experience and Systematic Review

Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer’s disease

Real-life reliability of plasma pTau181, Aβ 42 /Aβ 40 , and pTau181/Aβ 42 measured by Lumipulse G600II in predicting cerebrospinal fluid amyloid status

Automatic assessment of classical Alzheimer’s disease biomarkers in paired cerebrospinal fluid and plasma samples

Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis

A Comparison of the Lumipulse and Simoa Platforms

Fully automated measurement of plasma Aβ42/40 and p‐tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse

Plasma p-tau181 and amyloid markers in Alzheimer's disease: A comparison between Lumipulse and SIMOA

CSF Biomarkers in Longitudinal Alzheimer Disease Cohorts: Pre-Analytic Challenges

Diagnostic accuracy of automated Lumipulse plasma pTau-217 in Alzheimer's disease: a real-world study

Quantitative Measurement of Cerebrospinal Fluid Amyloid-β Species by Mass Spectrometry

Fully Automated Lumipulse Plasma Amyloid and phosphorylated Tau assays for Progression to Alzheimer’s disease in Mild Cognitive Impairment patients

Assessment of immunoprecipitation with subsequent immunoassays for the blood-based diagnosis of Alzheimer's disease

Alzheimer Disease Cerebrospinal Fluid Biomarkers in a Tertiary Neurology Practice

Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison

Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid-β1–42 and τ Proteins as Alzheimer Disease Biomarkers

Blood biomarkers for Alzheimer's disease with the Lumipulse automated platform: Age-effect and clinical value interpretation

Comparison of Serum and Cerebrospinal Fluid Neurofilament Light Chain Concentrations Measured by EllaTM and LumipulseTM in Patients with Cognitive Impairment

Diagnostic accuracy of automated Lumipulse plasma pTau-217 in Alzheimer disease

Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease